Sulfalene
Sulfalene (INN, USAN) or sulfametopyrazine (BAN) is a long-acting sulfonamide antibacterial used for the treatment of chronic bronchitis, urinary tract infections and malaria.[2][3] As of 2014 there were only two countries in which it is currently still marketed: Thailand and Ireland.[3]
![]() | |
| Clinical data | |
|---|---|
| Trade names | Eadazine, Kelfizina, Kelfizine W, Longum |
| Other names | Sulfametopyrazine |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral[1] |
| ATC code | |
| Pharmacokinetic data | |
| Protein binding | 60 to 80%[1] |
| Elimination half-life | 60 to 65 hours[1] |
| Excretion | Urinary[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.005.278 |
| Chemical and physical data | |
| Formula | C11H12N4O3S |
| Molar mass | 280.30 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
It was discovered by researchers at Farmitalia and first published in 1960 and was marketed as Kelfizina.[4][5]
See also
References
- "Sulfalene". MIMS Drug Information System. Retrieved 26 August 2011.
- DrugBank DB00664
- Brayfield A, ed. (9 May 2013). "Sulfametopyrazine". Martindale: The Complete Drug Reference. Pharmaceutical Press. Retrieved 28 March 2014.
- Baruffa G (1966). "Clinical trials in Plasmodium falciparum malaria with a long-acting sulphonamide". Transactions of the Royal Society of Tropical Medicine and Hygiene. 60 (2): 222–4. doi:10.1016/0035-9203(66)90030-7. PMID 5332105.
- Per prior citation, the first publication: Camerino B, Palamidessi G (1960). "Derivati della parazina II. Sulfonamdopir". Gazz Chim Ital (in Italian). 90: 1802–1815.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.
